Viking Therapeutics, Inc. - 10-Q Filing
Viking Therapeutics reported a net loss of $68.7 million for Q2 2026, driven by research and development expenses.
Tickers: $VKTX
More Regulatory news
- SusGlobal Energy Corp. - 10-Q Filing
- Ideal Power Inc. - 8-K Filing
- DIGI INTERNATIONAL INC - 8-K Filing
- ZeroStack Corp. - 8-K Filing
- Sound Point Meridian Capital, Inc. - 8-K Filing
- Boost Run Inc. - 8-K Filing
- INTERFACE INC - 8-K Filing
- Neonode Inc. - 10-Q Filing
- Virtuix Holdings Inc. - 8-K Filing
- Neonode Inc. - 8-K Filing